| HFrEF group (n = 54) | ||
---|---|---|---|
CR (n = 22) | NCR (n = 32) | P | |
Sex, male (%) | 17 (77.3%) | 25 (78.1%) | 1.000 |
Age (years) | 57.09 ± 9.17 | 57.03 ± 6.70 | 0.979 |
History of hypertension, n (%) | 13 (59.1%) | 14 (43.8%) | 0.406 |
History of diabetes, n (%) | 6 (27.3%) | 12 (37.5%) | 0.560 |
Smoking history, n (%) | 12 (54.5%) | 14 (43.8%) | 0.580 |
WBC (109/l), median (IQR) | 9.13 ± 3.22 | 10.53 ± 3.65 | 0.143 |
Platelet (109/l), median (IQR) | 217.45 ± 67.00 | 201.91 ± 71.71 | 0.420 |
HGB (g/l) | 139 ± 22.31 | 135.09 ± 18.09 | 0.500 |
Blood potassium (mmol/l) | 4.06 ± 0.40 | 3.99 ± 0.32 | 0.524 |
Urea nitrogen (mmol/l), median (IQR) | 6.19 ± 1.57 | 5.76 ± 2.34 | 0.422 |
Creatinine (umol/l), median (IQR) | 76.70 (64.25,92.85) | 77.40 (63.33,95.83) | 0.986 |
AST (U/l), median (IQR) | 108.30 (22.05, 353.72) | 113.00 (26.48, 380.45) | 0.418 |
ALT (U/l), median (IQR) | 44.05 (25.33, 76.45) | 51.10 (20.00, 87.07) | 0.758 |
HDL-C (mmol/l) | 1.09 ± 0.23 | 1.19 ± 0.28 | 0.155 |
non-HDL-C (mmol/l) | 3.58 ± 0.95 | 3.53 ± 1.24 | 0.869 |
TC (mmol/l), median (IQR) | 1.46 (1.07, 2.03) | 1.31 (0.96, 2.20) | 0.647 |
FBS (mmol/l), median (IQR) | 6.14 (5.51, 7.39) | 7.08 (5.82, 11.31) | 0.078 |
EDLV (mm) | 58.77 ± 5.15 | 56.84 ± 4.27 | 0.156 |
EF(%), median (IQR) | 34 (31, 37) | 34.5 (30, 38) | 0.965 |
Target lesion location | |||
 LAD, n (%) | 10 (45.5%) | 17 (53.1%) | 0.782 |
 LCX, n (%) | 2 (9.1%) | 2 (6.3%) | 1.000 |
 RCA, n (%) | 10 (45.5%) | 13 (40.6%) | 0.784 |
KILLIP class | |||
 I, n (%) | 0 (0.0%) | 0 (0.0%) | – |
 II, n (%) | 7 (31.8%) | 11 (34.4%) | 1.000 |
 III, n (%) | 12 (54.5%) | 10 (31.3%) | 0.101 |
 IV, n (%) | 3 (13.6%) | 11 (34.4%) | 0.119 |
MACE, n (%) | 4 (18.2%)** | 19 (59.4%) | 0.005 |
 Cardiogenic death, n (%) | 0 (0.0%)** | 10 (31.3%) | 0.003 |
 Rehospitalization, n (%) | 4 (18.2%) | 9 (28.1%) | 0.523 |
 Myocardial infarction, n (%) | 1 (4.5%) | 6 (18.8%) | 0.220 |
 Heart failure, n (%) | 3 (13.6%) | 3 (9.4%) | 0.678 |
 Stroke, n (%) | 0 (0.0%) | 0 (0.0%) | – |